Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Monday, March 11, 2019 at 4:00 PM to 4:30 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Advertisement

Currently submitted to: Journal of Medical Internet Research

Date Submitted: Aug 9, 2019
Open Peer Review Period: Aug 11, 2019 - Sep 30, 2019
(closed for review but you can still tweet)

NOTE: This is an unreviewed Preprint

Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note “no longer under consideration” will appear above).

Peer-review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a “Peer-Review Me” button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.

Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).

Final version: If our system detects a final peer-reviewed “version of record” (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.

Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.

Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.

A Smartphone-based Healthcare Chatbot to Promote Self-Management of Chronic Pain (SELMA): A Pilot Randomized Control Trial

  • Sandra Hauser-Ulrich; 
  • Hansjörg Künzli; 
  • Danielle Meier-Peterhans; 
  • Tobias Kowatsch; 

ABSTRACT

Background:

Ongoing pain is one of the most common diseases and has a major physical psychological, social and economic impact. A mobile health intervention utilizing a fully-automated text-based healthcare chatbot (TBHC) may offer an innovative way not only to deliver coping strategies and psychoeducation for pain management but also to build a working alliance between participant and the THCB.

Objective:

The objectives of this paper are twofold: (1) to describe the design and implementation of SELMA (painSELfMAnagement), a 2-month smartphone-based Cognitive Behavior Therapy (CBT) TBHC intervention for pain self-management of patients with ongoing or cyclic pain, and (2) to present findings from a pilot randomized controlled trial, in which effectiveness, influence of intention to change behavior and pain duration, working alliance, acceptance and adherence were evaluated.

Methods:

Participants were recruited online and in collaboration with pain experts and randomized to interact with SELMA for 8 weeks, either every day or every other day, concerning CBT-based pain management (n=59), or weekly concerning content not related to pain management (n=43). Pain-related impairment (primary outcome), general well-being, pain intensity and the bond scale of working alliance were measured at baseline and post-intervention, intention to change behavior and pain duration at baseline only, and acceptance post- intervention via self-report instruments. Adherence was assessed objectively via usage data.

Results:

From May 2018 till August 2018, 311 adults downloaded the SELMA app, 102 consented to participate and met the inclusion criteria. The average age of the 88 female (86.4%) and 14 male (13.6%) participants was 43.7 (SD=12.7) years. Baseline group comparison did not differ in any demographic or clinical variables. Pain intensity was reduced significantly (P=.05) and general well-being increased significantly (P=.01) in both groups. The intervention group reported no significant change in pain-related impairment (P=.68) compared to the wait-list control group post-intervention. The intention to change behavior was related positively to pain-related impairment (P=.01) and pain intensity (P=.01). Working alliance with the THCB SELMA was comparable to working alliance in guided internet therapies with human coaches. Participants enjoyed using the app, perceived it as useful and easy to use, and would recommend it to others. Overall, 52% adhered to the program by self-selecting coaching modules actively. Participants’ comments revealed an appreciation of the empathic and responsible interaction with the THCB SELMA. A main criticism was that there was no option to enter free text for patients’ own comments.

Conclusions:

SELMA is feasible, revealed mainly positive feedback and valuable suggestions for future revisions. For example, participants’ intention to change behavior or a more homogenous sample (e.g. with a specific type of chronic pain) should be considered in further tailoring SELMA. Clinical Trial: German Clinical Trials Register DRKS00017147; https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00017147, Swiss National Clinical Trial Portal: SNCTP000002712.


 Citation

Please cite as:

Hauser-Ulrich S, Künzli H, Meier-Peterhans D, Kowatsch T

A Smartphone-based Healthcare Chatbot to Promote Self-Management of Chronic Pain (SELMA): A Pilot Randomized Control Trial

JMIR Preprints. 09/08/2019:15806

DOI: 10.2196/preprints.15806

URL: https://preprints.jmir.org/preprint/15806


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.